Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corcept Therapeutics ( (CORT) ) just unveiled an announcement.
On September 10, 2025, Corcept Therapeutics announced that the FDA has accepted its New Drug Application for relacorilant, intended for treating patients with platinum-resistant ovarian cancer. This acceptance, based on positive Phase 2 and 3 trial results, marks a significant step towards offering a new treatment option for this challenging condition, with the FDA assigning a PDUFA date of July 11, 2026. Relacorilant, which has shown improved progression-free and overall survival rates without increasing safety risks, could potentially redefine treatment for this form of cancer.
The most recent analyst rating on (CORT) stock is a Buy with a $79.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.
Spark’s Take on CORT Stock
According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.
Corcept Therapeutics’ overall stock score reflects its strong financial performance and positive earnings call sentiment, which are slightly offset by valuation concerns and mixed technical indicators. The company’s robust financial health and strategic growth initiatives are significant strengths, while high P/E ratio and operational challenges present moderate risks.
To see Spark’s full report on CORT stock, click here.
More about Corcept Therapeutics
Corcept Therapeutics is a commercial-stage company based in Redwood City, California, specializing in the discovery and development of medications that modulate the hormone cortisol to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company has developed more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists and is conducting advanced clinical trials for various serious disorders, including hypercortisolism, solid tumors, ALS, and liver disease.
Average Trading Volume: 1,036,750
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.51B
Learn more about CORT stock on TipRanks’ Stock Analysis page.